For a drug product to be compensable through the Medical Assistance (MA) Program, the company (labeler) that markets the product must participate in the Federal Medicaid Drug Rebate Program.

The below revisions to the list, unless otherwise indicated, are effective July 1, 2023. Terminations and additions apply only to those National Drug Codes (NDCs) beginning with the five-digit labeler code indicated, and not to other NDCs that may be marketed by that company under a different labeler code.

**NEW and REINSTATED LABELERS**
- YARAL PHARMA INC (82347)
- SINGULAR DREAMER, LTC (83035)
- AUCTA PHARMACEUTICALS, INC. (73289)
- CURAE PHARMA360 INC. (73358)
- SCPHARMACEUTICALS INC. (71767)
- ACERTIS PHARMACEUTICALS (72989)
- BLUEBIRD BIO, INC. (73554)
- BROOKFIELD PHARMACEUTICALS, LLC (71351)
- ALK-ABELLO A S (52709)
- KARTHA PHARMACEUTICALS, INC. (73320)
- ELITE LABORATORIES, INC. (64850)
- VALINOR PHARMA, LLC (82625)
- MAINPOINTE PHARMACEUTICALS LLC (71269)

**TERMINATED LABELERS, MANDATORY AND VOLUNTARY**
- MEDEFIL, INC. (64253)
- PARSOLEX GMP CENTER, INC. (13845)
- VYNE PHARMACEUTICALS INC. (72356)
- JG PHARMA, INC. (72143)
- DERMIRA, INC. (70428)
- JOURNEY MEDICAL CORPORATION (69489)